IR-Med, Inc.
IR-Med, Inc.
No insider data available
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||||
Cash And Cash Equivalents At Carrying Value | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 2 | 2 | 3 | 4 | |||||
Assets Current | |||||||||||||||||
Assets Current | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 2 | 2 | 3 | 4 | |||||
Accounts Receivable Net Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Restricted Investments Noncurrent | - | - | 0 | - | - | - | 0 | - | - | - | - | - | |||||
Restricted Cash And Investments Noncurrent | 0 | 0 | - | - | - | - | - | - | - | - | - | - | |||||
Assets Noncurrent | |||||||||||||||||
Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Operating Lease Right Of Use Asset | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Assets | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 3 | 2 | 3 | 4 | |||||
Liabilities And Stockhold… | |||||||||||||||||
Long Term Loans Payable | - | - | - | - | - | - | 0 | - | - | - | - | - | |||||
Accounts Payable And Accrued Liabilities Current | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | |||||
Due To Officers Or Stockholders Current | - | - | - | - | - | - | - | - | - | - | 0 | - | |||||
Liabilities Current | |||||||||||||||||
Liabilities Current | 1 | 1 | 1 | - | - | - | 0 | 1 | 1 | 1 | 1 | - | |||||
Other Liabilities Current | - | - | - | - | - | - | - | - | - | 0 | 0 | - | |||||
Loans Payable Current | 0 | 0 | 0 | - | - | - | - | 0 | 0 | - | - | - | |||||
Convertible Debt | 0 | 0 | - | - | - | - | - | - | - | - | - | - | |||||
Long Term Debt And Capital Lease Obligations | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | |||||
Due To Officers Or Stockholders Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 0 | |||||
Liabilities Noncurrent | |||||||||||||||||
Liabilities Noncurrent | 0 | - | - | - | - | - | 0 | 0 | 0 | - | 0 | 0 | |||||
Operating Lease Liability Noncurrent | 0 | - | - | - | - | - | - | 0 | - | - | 0 | - | |||||
Liabilities | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Stockholders Equity | |||||||||||||||||
Additional Paid In Capital | 18 | 17 | 16 | 16 | 16 | 15 | 15 | 15 | 14 | 13 | 12 | 11 | |||||
Stockholders Equity | -1 | -0 | -0 | 0 | 0 | -0 | 0 | 1 | 2 | 2 | 3 | 4 | |||||
Retained Earnings Accumulated Deficit | -18 | -18 | -17 | -16 | -16 | -15 | -15 | -14 | -12 | -11 | -10 | -8 | |||||
Liabilities And Stockholders Equity | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 3 | 2 | 3 | 4 | |||||
Common Stock Par Or Stated Value Per Share | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | |||||
Common Stock Shares Authorized | 600 | 600 | 600 | 600 | 600 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | |||||
Common Stock Shares Issued | 77 | 72 | 71 | 71 | 71 | 70 | 70 | 70 | 70 | 69 | 69 | 69 | |||||
Shares Outstanding | 77 | 72 | 71 | - | - | - | 70 | 70 | 70 | 69 | 69 | 69 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -33.33% | -58.33% | -89.45% | -7.53% | 82.53% | 138.03% | - | - | - | - | - | - |
| 2024 | 11.11% | -33.33% | -33.33% | -40.00% | -11.67% | -16.67% | 0.00% | -42.17% | -36.75% | -77.78% | -73.33% | -82.67% |
| 2023 | 156.55% | 188.95% | 194.36% | 10.50% | 23.00% | 0.00% | 15.00% | 15.00% | 50.00% | -30.98% | -53.99% | -53.99% |
| 2022 | - | - | - | 0.00% | -2.40% | -4.80% | -48.99% | -60.00% | -58.50% | 3.32% | -4.33% | 42.36% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Metrics | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Metric history beyond 3 years is for subscribers only. Unlock 17+ years of history across 90+ calculated metrics Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liquidity Ratios | |||||||||||||||||
| Current Ratio | 0.12 | 0.13 | 0.38 | - | - | - | 1.79 | 2.87 | 4.05 | 3.44 | 4.62 | - | |||||
| Quick Ratio | 0.12 | 0.13 | 0.38 | - | - | - | 1.79 | 2.87 | 4.05 | 3.44 | 4.62 | - | |||||
| Working Capital | -684.00K | -536.00K | -340.00K | - | - | - | 375.00K | 1.05M | 1.83M | 1.53M | 2.40M | - | |||||
Leverage & Debt | |||||||||||||||||
| Debt to Equity | -1.28 | -1.25 | -1.85 | - | - | - | 1.74 | 0.46 | 0.31 | 0.38 | 0.27 | 0.15 | |||||
| Debt Ratio | 4.57 | 4.98 | 2.17 | - | - | - | 0.63 | 0.32 | 0.23 | 0.28 | 0.21 | 0.13 | |||||
Efficiency & Turnover | |||||||||||||||||
| Asset Turnover TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Receivables Turnover TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Per Share Metrics | |||||||||||||||||
| Diluted EPS TTM | 0.03 | 0.03 | 0.03 | 0.04 | 0.05 | 0.06 | 0.07 | 0.08 | 0.08 | 0.08 | 0.07 | 0.08 | |||||
| Free Cash Flow Per Share TTM | -0.01 | -0.02 | -0.02 | -0.03 | -0.03 | -0.04 | -0.05 | -0.05 | -0.05 | -0.05 | -0.05 | -0.05 | |||||
| Dividend Per Share TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Growth Metrics | |||||||||||||||||
| Net Income Growth (1Y) | -32.34% | -52.21% | -61.32% | -49.51% | -35.74% | -19.47% | 3.70% | 1.74% | -1.80% | - | - | - | |||||
| EPS Growth (1Y) | -35.52% | -53.10% | -62.19% | -50.88% | -36.89% | -20.73% | 0.97% | 1.57% | -2.92% | - | - | - | |||||
Valuation Metrics | |||||||||||||||||
| P/E TTM | 1.88 | 16.97 | 17.48 | 12.97 | 12.14 | 21.63 | 16.26 | 14.94 | 13.67 | 5.09 | 7.14 | 14.89 | |||||
| P/B TTM | -7.08 | -69.38 | -112.92 | 18,751.08 | 116.17 | -1,060.35 | 218.67 | 70.59 | 36.78 | 15.49 | 13.04 | 23.43 | |||||
| Market Cap | 4.43M | 34.20M | 33.20M | 37.50M | 42.17M | 91.19M | 79.82M | 85.56M | 73.86M | 26.64M | 33.79M | 83.84M | |||||
| Enterprise Value | 4.57M | 34.34M | 33.23M | 37.11M | 41.42M | 90.78M | 79.05M | 84.19M | 71.69M | 24.56M | 30.83M | 80.11M | |||||
Calculated Values | |||||||||||||||||
| Free Cash Flow TTM | -837.00K | -1.14M | -1.39M | -1.88M | -2.30M | -2.69M | -3.23M | -3.26M | -3.14M | -3.56M | -3.43M | -3.48M | |||||
| Net Debt | 145.00K | 138.00K | 28.00K | -392.00K | -753.00K | -408.00K | -767.00K | -1.37M | -2.17M | -2.08M | -2.96M | -3.73M | |||||
Per-Share and Margin | |||||||||||||||||
| EPS TTM | |||||||||||||||||
| Adjusted EPS TTM | |||||||||||||||||
| Cash Flow Per Share TTM | |||||||||||||||||
| Pretax Margin TTM | |||||||||||||||||
| Stock Comp to Revenue TTM | |||||||||||||||||
Turnover Ratios and Averages | |||||||||||||||||
| Average Assets | |||||||||||||||||
| Average Equity | |||||||||||||||||
| Average Inventory | |||||||||||||||||
| Average Receivables | |||||||||||||||||
| Average Accounts Payables | |||||||||||||||||
| Inventory Turnover TTM | |||||||||||||||||
| Payables Turnover TTM | |||||||||||||||||
| Days Inventory Outstanding TTM | |||||||||||||||||
| Days Payables Outstanding TTM | |||||||||||||||||
| Cash Conversion Cycle TTM | |||||||||||||||||
| Working Capital to Revenue | |||||||||||||||||
| Deferred Revenue to Revenue | |||||||||||||||||
Growth Rates | |||||||||||||||||
| Total Assets Growth (1Y) | |||||||||||||||||
| Total Assets Growth (3Y) | |||||||||||||||||
| Total Assets Growth (5Y) | |||||||||||||||||
| Dividends Paid Growth (1Y) | |||||||||||||||||
| Dividends Paid Growth (3Y) | |||||||||||||||||
| Dividends Paid Growth (5Y) | |||||||||||||||||
| EPS Growth (3Y) | |||||||||||||||||
| EPS Growth (5Y) | |||||||||||||||||
| Net Income Growth (3Y) | |||||||||||||||||
| Net Income Growth (5Y) | |||||||||||||||||
| Net Profit Margin Growth (1Y) | |||||||||||||||||
| Net Profit Margin Growth (3Y) | |||||||||||||||||
| Net Profit Margin Growth (5Y) | |||||||||||||||||
| Net Revenue Growth (3Y) | |||||||||||||||||
| Net Revenue Growth (5Y) | |||||||||||||||||
| Deferred Revenue Growth (1Y) | |||||||||||||||||
| Retained Earnings Growth (1Y) | |||||||||||||||||
Credit, Liquidity, Returns, Payout | |||||||||||||||||
| Cash Ratio | |||||||||||||||||
| Net Working Capital | |||||||||||||||||
| Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to Equity | |||||||||||||||||
| Altman A | |||||||||||||||||
| Altman B | |||||||||||||||||
| Altman C | |||||||||||||||||
| Altman D | |||||||||||||||||
| Altman E | |||||||||||||||||
| Altman Z-Score | |||||||||||||||||
| ROA TTM | |||||||||||||||||
| ROE TTM | |||||||||||||||||
| NOPAT TTM | |||||||||||||||||
| ROIC TTM | |||||||||||||||||
| Effective Tax Rate TTM | |||||||||||||||||
| Payout Ratio TTM | |||||||||||||||||
| Dilution Ratio | |||||||||||||||||
| Retained Earnings to Equity | |||||||||||||||||
| Treasury Stock to Equity | |||||||||||||||||
| Treasury Stock Change (1Y) | |||||||||||||||||
| Accrued to Current Liabilities | |||||||||||||||||
| NCAV | |||||||||||||||||
| NCAV Per Share TTM | |||||||||||||||||
Valuation Ratios | |||||||||||||||||
| P/CF TTM | |||||||||||||||||
| Dividend Yield TTM | |||||||||||||||||
| Free Cash Flow Yield TTM | |||||||||||||||||
| EV EBITDA TTM | |||||||||||||||||
| EV EBIT TTM | |||||||||||||||||
| Stock Compensation TTM | |||||||||||||||||
| Adjusted Net Income TTM | |||||||||||||||||
| Billings TTM | |||||||||||||||||
| Total Debt | |||||||||||||||||
| Invested Capital | |||||||||||||||||
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
IR-Med, Inc. (IRME) — SEC Financial Statements & Analysis
IR-Med, Inc. (IRME) is a electromedical & electrotherapeutic apparatus company, incorporated in NV. IR-Med, Inc. trades on OTC as: IRME. Based on its latest SEC filing (Form 10-Q, period ending 2025-06-30), IR-Med, Inc. reported a Debt-to-Equity ratio of -1.28x, a Price-to-Book (P/B) ratio of -7.08x (TTM), at a market cap of $4.43M. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- -1.28x
- P/B TTM
- -7.08x
- Market Cap
- $4.43M
Data as of 2025-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is IR-Med, Inc. in?
IR-Med, Inc. (IRME) operates in the Electromedical & Electrotherapeutic Apparatus industry.
What is IRME's market cap?
IR-Med, Inc. (IRME) has a market capitalization of $4.43M as of 2025-06-30.
What is IRME's P/E ratio?
IR-Med, Inc. (IRME)'s trailing twelve month P/E ratio is 1.88x as of 2025-06-30.
What exchange does IRME trade on?
IR-Med, Inc. (IRME) trades on the OTC.
Where is IR-Med, Inc. incorporated?
IR-Med, Inc. is incorporated in NV.